A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.

In the development of vaccines for epithelial tumors, the key targets are MUC1 proteins, which have a variable number of tandem repeats (VNTR) bearing tumor-associated carbohydrate antigens (TACAs), such as Tn and STn. A major obstacle in vaccine development is the low immunogenicity of the short MUC1 peptide. To overcome this obstacle, we designed, synthesized, and evaluated several totally synthetic self-adjuvanting vaccine candidates with self-assembly domains. These vaccine candidates aggregated into fibrils and displayed multivalent B-cell epitopes under mild conditions. Glycosylation of Tn antigen on the Thr residue of PDTRP sequence in MUC1 VNTR led to effective immune response. These vaccines elicited a high level antibody response without any adjuvant and induced antibodies that recognized human breast tumor cells. These vaccines appeared to act through a T-cell independent pathway and were associated with the activation of cytotoxic T cells. These fully synthetic, molecularly defined vaccine candidates had several features that hold promise for anticancer therapy.

[1]  C. Snapper,et al.  T cell-independent antigens type 2. , 1995, Annual review of immunology.

[2]  Jangwook P. Jung,et al.  Co-assembling peptides as defined matrices for endothelial cells. , 2009, Biomaterials.

[3]  J. Unkeless,et al.  The presence of two Fc receptors on mouse macrophages: evidence from a variant cell line and differential trypsin sensitivity , 1977, The Journal of experimental medicine.

[4]  G. Boons,et al.  The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. , 2004, Chemistry.

[5]  Zhongwu Guo,et al.  Recent development in carbohydrate-based cancer vaccines. , 2009, Current opinion in chemical biology.

[6]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[7]  H. Kunz,et al.  Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin. , 2005, Angewandte Chemie.

[8]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[9]  Yan‐Mei Li,et al.  Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. , 2011, Chemistry.

[10]  H. Kunz,et al.  Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy. , 2006, Current cancer drug targets.

[11]  M. Neuberger,et al.  Activation of mouse complement by monoclonal mouse antibodies , 1981, European journal of immunology.

[12]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[13]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[14]  E. Schmitt,et al.  Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. , 2010, Angewandte Chemie.

[15]  M. Wolfert,et al.  Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.

[16]  Jangwook P. Jung,et al.  A self-assembling peptide acting as an immune adjuvant , 2009, Proceedings of the National Academy of Sciences.

[17]  Peng Zou,et al.  Synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates and Their Evaluation as Vaccines , 2011 .

[18]  Zhongwu Guo,et al.  Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. , 2012, ACS chemical biology.

[19]  Ravibhushan Singh,et al.  MUC1: A target molecule for cancer therapy , 2007, Cancer biology & therapy.

[20]  E. Schmitt,et al.  A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. , 2005, Angewandte Chemie.

[21]  M. Skwarczynski,et al.  Peptide-based subunit nanovaccines. , 2011, Current drug delivery.

[22]  Yan‐Mei Li,et al.  Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response. , 2012, Angewandte Chemie.

[23]  Qian Wan,et al.  From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. , 2009, Journal of the American Chemical Society.

[24]  Brendan L Wilkinson,et al.  Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. , 2011, Angewandte Chemie.

[25]  John A. Robinson,et al.  Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. , 2007, Angewandte Chemie.

[26]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[27]  E. Schmitt,et al.  Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. , 2008, Angewandte Chemie.

[28]  D. Scheinberg,et al.  Toward a Prostate Specific Antigen-Based Prostate Cancer Diagnostic Assay: Preparation of Keyhole Limpet Hemocyanin -Conjugated Normal and Transformed Prostate Specific Antigen Fragments , 2008, Journal of the American Chemical Society.